1. In Vivo
  2. >>Business Strategy

What Next For Medtech And Investors Post-Coronavirus?

 
• By Ashley Yeo

If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.

Covid19_Ladder

Working through the COVID-19 crisis has, for many medtech businesses, resulted in an unexpected and steep uptick in activity. For the majority, however, it has meant much time spent scrutinizing coronavirus trending and analysis of when lockdowns will be eased.

When those timings are known, they can be gradually factored in by businesses, and a measured return to more normal activity can be planned

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo